Using imaging modalities to predict nanoparticle distribution and treatment efficacy in solid tumors: The growing role of ultrasound
Open Access
- 1 March 2024
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (2) , e1957
Abstract
Nanomedicine in oncology has not had the success in clinical impact that was anticipated in the early stages of the field's development. Ideally, nanomedicines selectively accumulate in tumor tissue and reduce systemic side effects compared to traditional chemotherapeutics. However, this has been more successful in preclinical animal models than in humans. The causes of this failure to translate may be related to the intra‐ and inter‐patient heterogeneity of the tumor microenvironment. Predicting whether a patient will respond positively to treatment prior to its initiation, through evaluation of characteristics like nanoparticle extravasation and retention potential in the tumor, may be a way to improve nanomedicine success rate. While there are many potential strategies to accomplish this, prediction and patient stratification via noninvasive medical imaging may be the most efficient and specific strategy. There have been some preclinical and clinical advances in this area using MRI, CT, PET, and other modalities. An alternative approach that has not been studied as extensively is biomedical ultrasound, including techniques such as multiparametric contrast‐enhanced ultrasound (mpCEUS), doppler, elastography, and super‐resolution processing. Ultrasound is safe, inexpensive, noninvasive, and capable of imaging the entire tumor with high temporal and spatial resolution. In this work, we summarize the in vivo imaging tools that have been used to predict nanoparticle distribution and treatment efficacy in oncology. We emphasize ultrasound imaging and the recent developments in the field concerning CEUS. The successful implementation of an imaging strategy for prediction of nanoparticle accumulation in tumors could lead to increased clinical translation of nanomedicines, and subsequently, improved patient outcomes.This article is categorized under: Diagnostic Tools In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery Emerging TechnologiesKeywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (R01EB025741, R01EB028144)
- National Institute of General Medical Sciences (T32GM007250)
- National Heart, Lung, and Blood Institute (F30HL160111)
This publication has 231 references indexed in Scilit:
- Pharmacokinetic modeling of PSMA‐targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancerMedical Physics, 2022
- Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric MicellesAdvanced Science, 2022
- Clinical implications of intratumor heterogeneity: challenges and opportunitiesJournal of Molecular Medicine, 2020
- Strategies to improve tumor penetration of nanomedicines through nanoparticle designWIREs Nanomedicine and Nanobiotechnology, 2018
- Simultaneous evaluation of vascular morphology, blood volume and transvascular permeability using SPION‐based, dual‐contrast MRI: imaging optimization and feasibility testNMR in Biomedicine, 2015
- High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatinCancer Chemotherapy and Pharmacology, 2014
- Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenograftsCancer Chemotherapy and Pharmacology, 2010
- Size Effect on Cell Uptake in Well‐Suspended, Uniform Mesoporous Silica NanoparticlesSmall, 2009
- Safety of ultrasound contrast agentsEuropean Radiology, 2005
- Effect of the surface charge of liposomes on their uptake by angiogenic tumor vesselsInternational Journal of Cancer, 2003